Clinical utility of ramucirumab in advanced gastric cancer
Matthew MK Chan,1,2 Katrin M Sjoquist,1,3 John R Zalcberg4 1NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; 2Department of Medical Oncology, Central Coast Cancer Centre, Gosford Hospital, Gosford, NSW, Australia; 3Cancer Care Centre, St George Hospital, Sydney, NSW, Austr...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2015-09-01
|
| Series: | Biologics: Targets & Therapy |
| Online Access: | https://www.dovepress.com/clinical-utility-of-ramucirumab-in-advanced-gastric-cancer-peer-reviewed-article-BTT |
| _version_ | 1823970939026538496 |
|---|---|
| author | Chan MMK Sjoquist KM Zalcberg JR |
| author_facet | Chan MMK Sjoquist KM Zalcberg JR |
| author_sort | Chan MMK |
| collection | DOAJ |
| description | Matthew MK Chan,1,2 Katrin M Sjoquist,1,3 John R Zalcberg4 1NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; 2Department of Medical Oncology, Central Coast Cancer Centre, Gosford Hospital, Gosford, NSW, Australia; 3Cancer Care Centre, St George Hospital, Sydney, NSW, Australia; 4School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia Abstract: Gastric cancer is currently the third most common cause of cancer deaths worldwide. Prognosis remains poor with most patients presenting with advanced or metastatic disease. A better understanding of angiogenesis has led to the investigation of drugs that inhibit the vascular endothelial growth factor (VEGF) pathway including anti-VEGF antibody therapy (eg, bevacizumab), inhibitors of angiogenic receptor tyrosine kinases (eg, sunitinib, sorafenib, apatinib, regorafenib), and inhibitors of vascular endothelial growth factor receptors (VEGFRs) (eg, ramucirumab). Ramucirumab, a VEGFR-2 inhibitor, is the first anti-angiogenic agent approved by the US Food and Drug Administration for use in the treatment of advanced gastric cancers. This review will focus on the clinical utility and potential use of ramucirumab in advanced gastric cancer. Keywords: ramucirumab, IMC-1121B, gastric cancer, vascular endothelial growth factor receptor-2, angiogenesis, targeted therapy |
| first_indexed | 2024-12-18T03:20:10Z |
| format | Article |
| id | doaj.art-753dbcc498084cff88f458d9a9342066 |
| institution | Directory Open Access Journal |
| issn | 1177-5491 |
| language | English |
| last_indexed | 2024-12-18T03:20:10Z |
| publishDate | 2015-09-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Biologics: Targets & Therapy |
| spelling | doaj.art-753dbcc498084cff88f458d9a93420662022-12-21T21:22:49ZengDove Medical PressBiologics: Targets & Therapy1177-54912015-09-012015default9310523791Clinical utility of ramucirumab in advanced gastric cancerChan MMKSjoquist KMZalcberg JRMatthew MK Chan,1,2 Katrin M Sjoquist,1,3 John R Zalcberg4 1NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; 2Department of Medical Oncology, Central Coast Cancer Centre, Gosford Hospital, Gosford, NSW, Australia; 3Cancer Care Centre, St George Hospital, Sydney, NSW, Australia; 4School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia Abstract: Gastric cancer is currently the third most common cause of cancer deaths worldwide. Prognosis remains poor with most patients presenting with advanced or metastatic disease. A better understanding of angiogenesis has led to the investigation of drugs that inhibit the vascular endothelial growth factor (VEGF) pathway including anti-VEGF antibody therapy (eg, bevacizumab), inhibitors of angiogenic receptor tyrosine kinases (eg, sunitinib, sorafenib, apatinib, regorafenib), and inhibitors of vascular endothelial growth factor receptors (VEGFRs) (eg, ramucirumab). Ramucirumab, a VEGFR-2 inhibitor, is the first anti-angiogenic agent approved by the US Food and Drug Administration for use in the treatment of advanced gastric cancers. This review will focus on the clinical utility and potential use of ramucirumab in advanced gastric cancer. Keywords: ramucirumab, IMC-1121B, gastric cancer, vascular endothelial growth factor receptor-2, angiogenesis, targeted therapyhttps://www.dovepress.com/clinical-utility-of-ramucirumab-in-advanced-gastric-cancer-peer-reviewed-article-BTT |
| spellingShingle | Chan MMK Sjoquist KM Zalcberg JR Clinical utility of ramucirumab in advanced gastric cancer Biologics: Targets & Therapy |
| title | Clinical utility of ramucirumab in advanced gastric cancer |
| title_full | Clinical utility of ramucirumab in advanced gastric cancer |
| title_fullStr | Clinical utility of ramucirumab in advanced gastric cancer |
| title_full_unstemmed | Clinical utility of ramucirumab in advanced gastric cancer |
| title_short | Clinical utility of ramucirumab in advanced gastric cancer |
| title_sort | clinical utility of ramucirumab in advanced gastric cancer |
| url | https://www.dovepress.com/clinical-utility-of-ramucirumab-in-advanced-gastric-cancer-peer-reviewed-article-BTT |
| work_keys_str_mv | AT chanmmk clinicalutilityoframucirumabinadvancedgastriccancer AT sjoquistkm clinicalutilityoframucirumabinadvancedgastriccancer AT zalcbergjr clinicalutilityoframucirumabinadvancedgastriccancer |